Literature DB >> 18097461

The anaplastic lymphoma kinase in the pathogenesis of cancer.

Roberto Chiarle1, Claudia Voena, Chiara Ambrogio, Roberto Piva, Giorgio Inghirami.   

Abstract

Tyrosine kinases are involved in the pathogenesis of most cancers. However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas. The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many molecular mechanisms. In this Review, we will analyse how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacological tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18097461     DOI: 10.1038/nrc2291

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  295 in total

Review 1.  Quantifying factors for the success of stratified medicine.

Authors:  Mark R Trusheim; Breon Burgess; Sean Xinghua Hu; Theresa Long; Steven D Averbuch; Aiden A Flynn; Alfons Lieftucht; Abhijit Mazumder; Judy Milloy; Peter M Shaw; David Swank; Jian Wang; Ernst R Berndt; Federico Goodsaid; Michael C Palmer
Journal:  Nat Rev Drug Discov       Date:  2011-10-31       Impact factor: 84.694

Review 2.  Emerging importance of ALK in neuroblastoma.

Authors:  Anna M Azarova; Gargi Gautam; Rani E George
Journal:  Semin Cancer Biol       Date:  2011-09-16       Impact factor: 15.707

3.  Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Authors:  Ryohei Katayama; Alice T Shaw; Tahsin M Khan; Mari Mino-Kenudson; Benjamin J Solomon; Balazs Halmos; Nicholas A Jessop; John C Wain; Alan Tien Yeo; Cyril Benes; Lisa Drew; Jamal Carlos Saeh; Katherine Crosby; Lecia V Sequist; A John Iafrate; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2012-01-25       Impact factor: 17.956

Review 4.  Hydrogels and scaffolds for immunomodulation.

Authors:  Ankur Singh; Nicholas A Peppas
Journal:  Adv Mater       Date:  2014-08-25       Impact factor: 30.849

Review 5.  Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

Review 6.  ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.

Authors:  Francesca Casaluce; Assunta Sgambato; Paolo Maione; Antonio Rossi; Carmine Ferrara; Alba Napolitano; Giovanni Palazzolo; Fortunato Ciardiello; Cesare Gridelli
Journal:  Target Oncol       Date:  2013-01-17       Impact factor: 4.493

7.  Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.

Authors:  Michal Marzec; Krzysztof Halasa; Xiaobin Liu; Hong Y Wang; Mangeng Cheng; Donald Baldwin; John W Tobias; Stephen J Schuster; Anders Woetmann; Qian Zhang; Suzanne D Turner; Niels Ødum; Mariusz A Wasik
Journal:  J Immunol       Date:  2013-11-11       Impact factor: 5.422

8.  Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.

Authors:  Soeren Latteyer; Vera Tiedje; Katharina König; Saskia Ting; Lukas C Heukamp; Lydia Meder; Kurt Werner Schmid; Dagmar Führer; Lars Christian Moeller
Journal:  Endocrine       Date:  2016-10-01       Impact factor: 3.633

Review 9.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

10.  C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway.

Authors:  Natasa Anastasov; Irina Bonzheim; Martina Rudelius; Margit Klier; Therese Dau; Daniela Angermeier; Justus Duyster; Stefania Pittaluga; Falko Fend; Mark Raffeld; Leticia Quintanilla-Martinez
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.